Clinical Trial Update: Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial of dasatinib for advanced hepatocellular carcinoma that could not be removed surgically was terminated; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-03-20